Arachidonate-enriched triglyceride oil does not promote tumor development in a rat medium-term multi-organ carcinogenesis model

2012 ◽  
Vol 50 (8) ◽  
pp. 2780-2791 ◽  
Author(s):  
Norio Imai ◽  
Mayumi Kawabe ◽  
Seiko Tamano ◽  
Yuko Doi ◽  
Hironao Nakashima ◽  
...  
Keyword(s):  
Tumor Development ◽  
Medium Term ◽  
Promote Tumor Development

Mesenchymal stromal cells promote tumor development and progression

Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S36
Author(s):  
Gyeongsin Park ◽  
Byunghoo Song ◽  
Kyo Young Song ◽  
Yang-Guk Chung ◽  
Youn-Soo Lee
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Tumor Development ◽  
Promote Tumor Development

scholarly journals Tumor macrophages are pivotal constructors of tumor collagenous matrix

2016 ◽  
Vol 213 (11) ◽  
pp. 2315-2331 ◽  
Author(s):  
Ran Afik ◽  
Ehud Zigmond ◽  
Milena Vugman ◽  
Mordehay Klepfish ◽  
Elee Shimshoni ◽  
...  
Keyword(s):  
Tumor Development ◽  
Molecular Signature ◽  
Matrix Remodeling ◽  
Matricellular Proteins ◽  
Tumor Invasiveness ◽  
Composition And Structure ◽  
Tumor Tissues ◽  
Collagenous Matrix ◽  
Macrophage Subpopulations ◽  
Promote Tumor Development

Tumor-associated macrophages (TAMs) promote tumor development, invasion, and dissemination by various mechanisms. In this study, using an orthotopic colorectal cancer (CRC) model, we found that monocyte-derived TAMs advance tumor development by the remodeling of its extracellular matrix (ECM) composition and structure. Unbiased transcriptomic and proteomic analyses of (a) TAM-abundant and -deficient tumor tissues and (b) sorted tumor-associated and -resident colonic macrophage subpopulations defined a distinct TAM-induced ECM molecular signature composed of an ensemble of matricellular proteins and remodeling enzymes they provide to the tumor microenvironment. Remarkably, many of these ECM proteins are specifically increased in human CRC versus healthy colon. Specifically, we demonstrate that although differentiating into TAMs, monocytes up-regulate matrix-remodeling programs associated with the synthesis and assembly of collagenous ECM, specifically collagen types I, VI, and XIV. This finding was further established by advanced imaging showing that TAMs instruct the deposition, cross-linking, and linearization of collagen fibers during tumor development, especially at areas of tumor invasiveness. Finally, we show that cancer-associated fibroblasts are significantly outnumbered by TAMs in this model and that their expression of collagen XIV and I is reduced by TAM deficiency. Here, we outline a novel TAM protumoral function associated with building of the collagenous ECM niche.

scholarly journals Extracellular MicroRNAs as Intercellular Mediators and Noninvasive Biomarkers of Cancer

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3455
Author(s):  
Blanca Ortiz-Quintero
Keyword(s):  
Cancer Cells ◽  
Cancer Detection ◽  
Tumor Development ◽  
Bodily Fluids ◽  
Different Types ◽  
Extracellular Mirnas ◽  
Subcellular Compartmentalization ◽  
Noninvasive Biomarkers ◽  
Promote Tumor Development

MicroRNAs (miRNAs) are released by different types of cells through highly regulated mechanisms under normal and pathological conditions. These extracellular miRNAs can be delivered into recipient cells for functional purposes, acting as cell-to-cell signaling mediators. It has been discovered that cancer cells release miRNAs into their surroundings, targeting normal cells or other cancer cells, presumably to promote tumor development and progression. These extracellular miRNAs are associated with oncogenic mechanisms and, because they can be quantified in blood and other bodily fluids, may be suitable noninvasive biomarkers for cancer detection. This review summarizes recent evidence of the role of extracellular miRNAs as intercellular mediators, with an emphasis on their role in the mechanisms of tumor development and progression and their potential value as biomarkers in solid tumors. It also highlights the biological characteristics of extracellular miRNAs that enable them to function as regulators of gene expression, such as biogenesis, gene silencing mechanisms, subcellular compartmentalization, and the functions and mechanisms of release.

scholarly journals RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development

2013 ◽  
Vol 110 (5) ◽  
pp. 1720-1725 ◽  
Author(s):  
W.-j. Su ◽  
J.-s. Fang ◽  
F. Cheng ◽  
C. Liu ◽  
F. Zhou ◽  
...  
Keyword(s):  
Cancer Cell ◽  
Tumor Development ◽  
Cell Types ◽  
P53 Expression ◽  
Promote Tumor Development

scholarly journals Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Atsunobu Takeda ◽  
Eiichi Hasegawa ◽  
Shintaro Nakao ◽  
Keijiro Ishikawa ◽  
Yusuke Murakami ◽  
...  
Keyword(s):  
B Cell ◽  
Poor Prognosis ◽  
Tumor Development ◽  
Rank Test ◽  
Control Group ◽  
Log Rank Test ◽  
Vitreoretinal Lymphoma ◽  
Infectious Uveitis ◽  
Cancer Types ◽  
Promote Tumor Development

Abstract Vitreoretinal lymphoma (VRL) is a rare disease of B-cell origin with poor prognosis. Regulatory cytokines promote tumor development by suppressing antitumor immunity in several cancer types, including B-cell malignancies. To identify the regulatory cytokines associated with poor prognosis in patients with B-cell VRL, we determined the regulatory cytokines profiles in the vitreous humor of patients with VRL. This retrospective study included 22 patients with VRL, 24 with non-infectious uveitis (NIU), and 20 with idiopathic epiretinal membrane (control). Vitreous concentrations of regulatory cytokines were assessed using a cytometric beads assay and association with clinical data was examined. IL-35 and soluble IL-2 receptor α levels were significantly higher in patients with VRL and NIU than those in the control group. The 5-year overall survival (OS) rates for the group with high intravitreal IL-35 was significantly poorer than those for the group with low intravitreal IL-35, who were diagnosed with VRL at the onset (P = 0.024, log-rank test). The 5-year OS rates with intravitreal IL-35 levels above and below the median were 40.0% and 83.3%, respectively. Our results suggest that high intravitreal IL-35 levels indicate poor prognosis for patients diagnosed with B-cell VRL at the onset.

scholarly journals Phenotypic and Functional Diversities of Myeloid-Derived Suppressor Cells in Autoimmune Diseases

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Huijuan Ma ◽  
Chang-Qing Xia
Keyword(s):  
Autoimmune Diseases ◽  
Tumor Development ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Beneficial Effects ◽  
Adaptive Immune ◽  
The Past ◽  
Animal Tumor ◽  
Promote Tumor Development

Myeloid-derived suppressor cells (MDSCs) are identified as a heterogeneous population of cells with the function to suppress innate as well as adaptive immune responses. The initial studies of MDSCs were primarily focused on the field of animal tumor models or cancer patients. In cancer, MDSCs play the deleterious role to inhibit tumor immunity and to promote tumor development. Over the past few years, an increasing number of studies have investigated the role of MDSCs in autoimmune diseases. The beneficial effects of MDSCs in autoimmunity have been reported by some studies, and thus, immunosuppressive MDSCs may be a novel therapeutic target in autoimmune diseases. There are some controversial findings as well. Many questions such as the activation, differentiation, and suppressive functions of MDSCs and their roles in autoimmune diseases remain unclear. In this review, we have discussed the current understanding of MDSCs in autoimmune diseases.

Sign in / Sign up

Export Citation Format

Share Document